These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 7533355

  • 1. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization.
    Schwartz M, Holst B, Facklam D, Buell D.
    Transplant Proc; 1995 Feb; 27(1):1107. PubMed ID: 7533355
    [No Abstract] [Full Text] [Related]

  • 2. Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group.
    Bäckman L, Levy MF, Klintmalm G.
    Transplant Proc; 1995 Feb; 27(1):1124. PubMed ID: 7533361
    [No Abstract] [Full Text] [Related]

  • 3. FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients.
    D'Alessandro AM, Kalayoglu M, Pirsch JD, Corwith C, Knechtle SJ, Reed A, Belzer FO.
    Transplant Proc; 1991 Dec; 23(6):2987-8. PubMed ID: 1721335
    [No Abstract] [Full Text] [Related]

  • 4. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES, Bruce DS, Josephson M, Newell KA, Piper JB, Millis JM, Cronin D, Whitman G, Ruebe M, Thistlethwaite JR.
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [Abstract] [Full Text] [Related]

  • 5. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
    Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):679-88. PubMed ID: 7679840
    [Abstract] [Full Text] [Related]

  • 6. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
    Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):641-3. PubMed ID: 7679828
    [No Abstract] [Full Text] [Related]

  • 7. Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation.
    Winkler M, Ringe B, Jost U, Gubernatis G, Pichlmayr R.
    Transplant Proc; 1993 Aug; 25(4):2688-90. PubMed ID: 7689277
    [No Abstract] [Full Text] [Related]

  • 8. FK 506 treatment of intractable rejection after liver transplantation.
    Jost U, Winkler M, Ringe B, Rodeck B, Pichlmayr R.
    Transplant Proc; 1993 Aug; 25(4):2686-7. PubMed ID: 7689276
    [No Abstract] [Full Text] [Related]

  • 9. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group.
    Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):635-7. PubMed ID: 7679826
    [No Abstract] [Full Text] [Related]

  • 10. Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant.
    Jain AB, Todo S, Fung JJ, Venkataramanan R, Day R, Bryant J, Abu-Elmagd KM, Alessiani M, Takaya S, Tzakis A.
    Transplant Proc; 1991 Dec; 23(6):3023-5. PubMed ID: 1721347
    [No Abstract] [Full Text] [Related]

  • 11. Spontaneous proliferation of peripheral blood mononuclear cells as an indicator for insufficient plasma levels of FK 506 in the early phase after liver transplantation.
    Kato H, Inamoto T, Kanaya S, Uyama S, Uemoto S, Tanaka K, Yamaoka Y.
    Transplant Proc; 1994 Apr; 26(2):893-5. PubMed ID: 7513481
    [No Abstract] [Full Text] [Related]

  • 12. FK 506 as treatment of late acute rejection in liver transplant patients.
    Rucay P, Samuel D, Farges O, Reynes M, Bismuth H.
    Transplant Proc; 1995 Feb; 27(1):1105-6. PubMed ID: 7533354
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients.
    Hebert MF, Ascher NL, Lake JR, Roberts JP.
    Transplant Proc; 1991 Dec; 23(6):3109-10. PubMed ID: 1721373
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
    Bismuth H.
    Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
    [No Abstract] [Full Text] [Related]

  • 15. Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation.
    Winkler M, Pichlmayr R, Neuhaus P, McMaster P, Calne R, Otto G, Williams R, Bismuth H, Groth C.
    Transpl Int; 1994 Feb; 7 Suppl 1():S58-63. PubMed ID: 11271312
    [Abstract] [Full Text] [Related]

  • 16. Compassionate use of FK 506 in liver transplantation.
    Murio JE, Balsells J, Lázaro JL, Charco R, Margarit C.
    Transplant Proc; 1995 Aug; 27(4):2336. PubMed ID: 7544501
    [No Abstract] [Full Text] [Related]

  • 17. Clinical use of FK 506 in liver transplantation.
    Klintmalm GB.
    Transplant Proc; 1996 Apr; 28(2):974-6. PubMed ID: 8623484
    [Abstract] [Full Text] [Related]

  • 18. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation.
    Sher LS, Cosenza CA, Petrovic LM, Rojter S, Hoffman A, Lopez RR, Meehan M, Pan SH, Vierling J, Makowka L.
    Transplant Proc; 1996 Apr; 28(2):1011-3. PubMed ID: 8623212
    [No Abstract] [Full Text] [Related]

  • 19. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients.
    Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R.
    Transplant Proc; 1991 Dec; 23(6):3153-5. PubMed ID: 1721389
    [No Abstract] [Full Text] [Related]

  • 20. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
    Jonas S, Kling N, Bechstein WO, Blumhardt G, Lohmann R, Lobeck H, Neuhaus P.
    Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.